Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
Six men and one woman with mild anemia due to beta-thalassemia trait and major iron overload attributable to concomitant primary hemochromatosis were treated by erythrocytapheresis to remove iron, combined with subcutaneous desferrioxamine in the four cases with greater iron load. Depletion was achieved by iron removal of 4.5-15.1 g after 9-24 months' treatment. No side effects were observed, suggesting that such a regimen is effective and safe in this particular subgroup of hemochromatotics.
Cesana
M
M
Patologia Medica III, Istituto di Scienze Mediche, Università di Milano, Italy.
Mandelli
C
C
Tiribelli
C
C
Bianchi
P A
PA
Conte
D
D
D000328:Adult; D001781:Blood Component Removal; D003676:Deferoxamine / Q000627:therapeutic use*; D004912:Erythrocytes; D005260:Female; D005293:Ferritins / Q000097:blood; D006432:Hemochromatosis / Q000150:complications / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D013789:Thalassemia / Q000150:complications*; D014168:Transferrin / Q000378:metabolism
D014168:Transferrin; D005293:Ferritins; D003676:Deferoxamine